Proxalutamide reduces COVID-19 risk: real-time meta-analysis of 4 studies (Version 11)

Significantly lower risk is seen for mortality, ventilation, hospitalization, recovery, and viral clearance. 4 studies from 2 independent teams in 2 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 78% [70‑83%] lower risk. Results are similar for peer-reviewed studies. Currently all studies are RCTs.

Control Proxalutamide

Studies to date are from only 2 different groups.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. All data and sources to reproduce this analysis are in the appendix.

Zheng et al. present another meta-analysis for proxalutamide, showing significant improvements for mortality, mechanical ventilation, hospitalization, and clinical improvement.